Nonclinical Development

Nonclinical development generates and interprets the pharmacology, safety, and toxicology data needed before and alongside human studies. The package informs starting dose, exposure margins, target organ risks, and what regulators will expect in an IND or CTA. Weak nonclinical planning shows up later as repeat studies, clinical holds, or gaps in Module 2 and Module 4 that slow the filing and force expensive catch-up work under time pressure.

Viltis works with sponsors to shape nonclinical strategies that match modality, indication, and clinical plan rather than a template checklist. We help prioritize study types, species selection rationale, and timing relative to first-in-human and later phases, and we interpret results in language clinical and regulatory teams can use. When CROs run the studies, we stay focused on design quality, data review, and how findings change the development path. We also help teams decide which exploratory studies add decision value and which mainly add cost and delay.

Nonclinical plans should stay coupled to CMC and clinical reality. Formulation changes, impurity profiles, and route of administration shifts can invalidate earlier safety assumptions if nobody reconnects the packages. Viltis helps keep those interfaces visible so toxicology and pharmacology investments remain relevant as the candidate evolves through development gates.

Nonclinical development support commonly includes

• Nonclinical strategy and study sequencing
• IND-enabling package planning and gap review
• Pharmacology and safety data interpretation
• Alignment with FIH dose and clinical design
• CRO oversight for study design and delivery
• Support for Module 2 and Module 4 narratives
• Issue management when findings surprise the plan

Good nonclinical work answers specific questions before patients are dosed. Viltis consultants help teams spend study budget on decisions that matter for the next clinical gate, and document the rationale so reviewers can follow the logic without a scavenger hunt. When unexpected findings appear, we help frame options quickly: additional studies, protocol changes, or a clear case that the signal is manageable with monitoring. The point is a coherent path forward, not a thicker binder. If an IND clock is fixed and the package is incomplete, we help triage what must be generated now versus what can be justified as a post-filing commitment.